SYMBIOTEC PHARMALAB | FROM STEROID API LEADER TO CDMO & COMPLEX INJECTABLES

CURRENT POSITION
- Listed at around ₹1,100, nearly 11% above the IPO price of ₹988.
- Global leader in steroid APIs.
- FY26 Revenue: ₹869 Cr | PAT: ₹110 Cr.
- At ₹1,100, market cap is ~₹6,950 Cr, valuing the company at ~63x FY26 earnings.

CAPACITY & REVENUE EXPANSION
- Expanded asset base has the potential to support revenue of ₹2,000+ Cr — more than 2x FY26 levels.
- Fermentation capacity is being expanded from 300 KL to 700 KL.
- The key opportunity is not just volume growth, but moving toward higher-value products.

CDMO & COMPLEX INJECTABLES
- CDMO and complex injectables are expected to become a much larger part of the business by FY30.
- New categories can deliver ~10 percentage points higher gross margins.
- EBITDA margins could be ~3–7 percentage points higher than the existing business.
- Long-term CDMO contracts provide better revenue visibility.
- Double-chamber vials and the complex-injectables pipeline add further growth optionality beyond the existing steroid API portfolio.

WHAT CAN DRIVE EARNINGS
- 2x+ potential revenue capacity.
- 300 KL → 700 KL fermentation expansion.
- Increasing contribution from CDMO and complex injectables.
- Better product mix supporting gross and EBITDA margin expansion.
- Long-term contracts improving business visibility.

KEY RISK / MONITORABLE
- At ~63x FY26 earnings, meaningful growth is already priced into the valuation.
- The key question is whether Symbiotec can execute the capacity expansion and ramp up utilisation fast enough.
- Future returns will depend on the pace of revenue growth, capacity utilisation and margin improvement.

KEY TAKEAWAY
Symbiotec is potentially moving from a steroid API-led business to a higher-value CDMO + complex-injectables platform. The ₹2,000+ Cr revenue opportunity, 700 KL fermentation capacity and potential margin expansion create a strong long-term growth story — but at ~63x FY26 earnings, execution and capacity utilisation will be critical to justify the valuation.

Must JOIN 👇
Daily Live Business Updates
@Stockupdate9